AAPL   320.59 (-0.39%)
MSFT   182.30 (-0.29%)
FB   228.22 (-1.59%)
GOOGL   1,426.47 (-0.59%)
AMZN   2,458.61 (-0.50%)
NVDA   347.79 (-1.27%)
CGC   16.39 (-0.55%)
GE   7.11 (+5.18%)
TSLA   889.42 (-0.97%)
AMD   52.50 (-2.13%)
T   30.88 (-0.16%)
DIS   118.15 (-0.52%)
BAC   24.89 (+1.14%)
BA   153.17 (+1.18%)
AAPL   320.59 (-0.39%)
MSFT   182.30 (-0.29%)
FB   228.22 (-1.59%)
GOOGL   1,426.47 (-0.59%)
AMZN   2,458.61 (-0.50%)
NVDA   347.79 (-1.27%)
CGC   16.39 (-0.55%)
GE   7.11 (+5.18%)
TSLA   889.42 (-0.97%)
AMD   52.50 (-2.13%)
T   30.88 (-0.16%)
DIS   118.15 (-0.52%)
BAC   24.89 (+1.14%)
BA   153.17 (+1.18%)
AAPL   320.59 (-0.39%)
MSFT   182.30 (-0.29%)
FB   228.22 (-1.59%)
GOOGL   1,426.47 (-0.59%)
AMZN   2,458.61 (-0.50%)
NVDA   347.79 (-1.27%)
CGC   16.39 (-0.55%)
GE   7.11 (+5.18%)
TSLA   889.42 (-0.97%)
AMD   52.50 (-2.13%)
T   30.88 (-0.16%)
DIS   118.15 (-0.52%)
BAC   24.89 (+1.14%)
BA   153.17 (+1.18%)
AAPL   320.59 (-0.39%)
MSFT   182.30 (-0.29%)
FB   228.22 (-1.59%)
GOOGL   1,426.47 (-0.59%)
AMZN   2,458.61 (-0.50%)
NVDA   347.79 (-1.27%)
CGC   16.39 (-0.55%)
GE   7.11 (+5.18%)
TSLA   889.42 (-0.97%)
AMD   52.50 (-2.13%)
T   30.88 (-0.16%)
DIS   118.15 (-0.52%)
BAC   24.89 (+1.14%)
BA   153.17 (+1.18%)
Log in

NASDAQ:TXMDTherapeuticsMD Stock Price, Forecast & News

$1.16
-0.03 (-2.52 %)
(As of 06/2/2020 12:24 PM ET)
Add
Compare
Today's Range
$1.14
Now: $1.16
$1.24
50-Day Range
$0.87
MA: $1.15
$1.76
52-Week Range
$0.85
Now: $1.16
$4.32
Volume140,173 shs
Average Volume4.28 million shs
Market Capitalization$315.15 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida.
Read More
TherapeuticsMD logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXMD
Previous SymbolNYSEMKT:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$49.65 million
Book Value$0.03 per share

Profitability

Net Income$-176,150,000.00
Net Margins-333.88%

Miscellaneous

Employees348
Market Cap$315.15 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

How has TherapeuticsMD's stock been impacted by COVID-19 (Coronavirus)?

TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TXMD shares have decreased by 23.7% and is now trading at $1.1599. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TherapeuticsMD?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TherapeuticsMD.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for TherapeuticsMD.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) announced its earnings results on Wednesday, May, 6th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The company earned $12.25 million during the quarter, compared to the consensus estimate of $11.48 million. TherapeuticsMD had a negative return on equity of 1,170.63% and a negative net margin of 333.88%. View TherapeuticsMD's earnings history.

What guidance has TherapeuticsMD issued on next quarter's earnings?

TherapeuticsMD issued an update on its first quarter 2020 After-Hours earnings guidance on Thursday, March, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11 million, compared to the consensus revenue estimate of $11.64 million.

What price target have analysts set for TXMD?

9 brokerages have issued 12 month target prices for TherapeuticsMD's stock. Their forecasts range from $3.00 to $15.00. On average, they anticipate TherapeuticsMD's share price to reach $8.67 in the next year. This suggests a possible upside of 647.2% from the stock's current price. View analysts' price targets for TherapeuticsMD.

Has TherapeuticsMD been receiving favorable news coverage?

Press coverage about TXMD stock has trended very positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. TherapeuticsMD earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutTherapeuticsMD.

Who are some of TherapeuticsMD's key competitors?

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), Cleveland-Cliffs (CLF), NVIDIA (NVDA), CannTrust (CNTTF), Micron Technology (MU), Horizon Therapeutics (HZNP) and Novavax (NVAX).

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the following people:
  • Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 49, Pay $1.22M)
  • Mr. John C. K. Milligan IV, Pres & Sec. (Age 58, Pay $794.68k)
  • Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 62, Pay $659.3k)
  • Mr. Mitchell L. Krassan, Exec. VP and Chief Strategy & Performance Officer (Age 54, Pay $560.53k)
  • Mr. Michael Donegan, VP of Fin. (Age 52, Pay $378.3k)

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (7.10%), BlackRock Inc. (6.61%), Bank of New York Mellon Corp (4.67%), Franklin Resources Inc. (2.43%), C WorldWide Group Holding A S (2.28%) and State Street Corp (2.01%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View institutional ownership trends for TherapeuticsMD.

Which institutional investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Invesco Ltd., Two Sigma Investments LP, Morgan Stanley, Greenwood Capital Associates LLC, JPMorgan Chase & Co., Bank of New York Mellon Corp, and BlackRock Inc.. View insider buying and selling activity for TherapeuticsMD.

Which institutional investors are buying TherapeuticsMD stock?

TXMD stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Nuveen Asset Management LLC, Geode Capital Management LLC, Twin Focus Capital Partners LLC, Bay Colony Advisory Group Inc d b a Bay Colony Advisors, Raymond James & Associates, Spark Investment Management LLC, and Arizona State Retirement System. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio, and Tommy G Thompson. View insider buying and selling activity for TherapeuticsMD.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $1.16.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $315.12 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 348 workers across the globe.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is www.therapeuticsmd.com.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.